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The osteopetroses are a heterogeneous group of conditions characterized by a bone-density increase due to impaired
bone resorption. As well as the two or more autosomal recessive types, two autosomal dominant forms of osteo-
petrosis, differentiated by clinical and radiological signs, are described. Autosomal dominant osteopetrosis (ADO)
type II, also known as “Albers-Scho¨nberg disease,” is characterized by sclerosis, predominantly involving the spine
(vertebral end-plate thickening, or Rugger-Jersey spine), the pelvis (“bone-within-bone” structures), and the skull
base. An increased fracture rate can be observed in these patients. By linkage analysis, the presence, on chromosome
1p21, of a gene causing ADO type II was previously suggested. However, analysis of further families with ADO
type II indicated genetic heterogeneity within ADO type II, with the chromosome 1p21 locus being only a minor
locus. We now perform a genomewide linkage scan of a French extended family with ADO type II, which allows
us to localize an ADO type II gene on chromosome 16p13.3. Analysis of microsatellite markers in five further
families with ADO type II could not exclude this chromosomal region. A summed maximum LOD score of 12.70
was generated with marker D16S3027, at a recombination fraction (v) of 0. On the basis of the key recombinants
in the families, a candidate region of 8.4 cM could be delineated, flanked by marker D16S521, on distal side, and
marker D16S423, on the proximal side. Surprisingly, one of the families analyzed is the Danish family previously
suggested to have linkage to chromosome 1p21. Linkage to chromosome 16p13.3 clearly cannot be excluded in
this family, since a maximum LOD score of 4.21 at is generated with marker D16S3027. Because at presentvp 0
no other family with ADO type II has proved to have linkage to chromosome 1p21, we consider the most likely
localization of the disease-causing gene in this family to be to chromosome 16p13.3. This thus reopens the possibility
that ADO type II is genetically homogeneous because of a single gene on chromosome 16p13.3.
Bone turnover is a highly regulated phenomenon that
involves bone resorption by osteoclasts and bone for-
mation by osteoblasts. Sclerosing bone disorders thus
result from either an excess of bone formation or a defect
of bone resorption or, in some conditions, a combination
of both. The osteopetrosis group encompasses120 forms
of mammalian diseases, including 4 human forms
(Shapiro 1993; Felix et al. 1996). Some genes underlying
different types of human osteopetrosis have been iden-
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tified. Recessive osteopetrosis with renal tubular acidosis
(MIM 259730) results from a mutation in the gene en-
coding carbonic anhydrase type II (Sly et al. 1983), and
malignant recessive osteopetrosis can be due to muta-
tions either in the TCIRG1 gene (MIM 604592)—en-
coding the a3 subunit of the vacuolar proton pump
(Frattini et al. 2000; Kornak et al. 2000)—or in the
CLCN7 gene (MIM 602727)—encoding an osteoclast-
specific chloride channel (Kornak et al. 2001).
The autosomal dominant form generally presentswith
a milder phenotype and is therefore also known as the
“benign” type. On the basis of radiological and clinical
differences, two subtypes have been recognized (Ander-
sen and Bollerslev 1987; Bollerslev and Andersen 1988).
Autosomal dominant osteopetrosis (ADO) type II (MIM
166600) was the first type of osteopetrosis recognized,
as described—as early as 1904—by Albers-Scho¨nberg
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Figure 1 Radiological features of female patient CII-2 at age 45 years. A, Lumbar-spine standard radiograph showing thickened and sclerotic
vertebral end plates. This feature, usually named “Rugger-Jersey spine,” is characteristic of ADO type II. B, Pelvic-front standard radiograph with
bone-within-bone sign—usually consisting of concentric bands of sclerosis in round and flat bones, especially in the iliac wings.
(1904). In other types of osteopetrosis, the phenotype is
an inherited sclerosing bone disorder that involves a
bone-resorption defect (Bollerslev 1989). Clinical man-
ifestations of ADO type II are dominated by long-bone
fractures, which occur, with or without trauma, in
75% of the patients (Be´nichou et al. 2000b). Other
classic manifestations of ADO type II include hip osteo-
arthritis, facial nerve palsy, and mandibular osteomye-
litis. Many patients undergo several orthopedic proce-
dures that are often complicated owing to the hardness
and the brittleness of their skeletons. However, 20%–
40% of the patients remain asymptomatic (Bollerslev
1989; Be´nichou et al. 2000b). The estimated prevalence
of ADO type II is from 0.2/100,000, in Brazil, to 5.5/
100,000, in Denmark (Salzano 1961; Bollerslev 1987).
Skeletal alterations of patients with ADO type II are
often so dramatic that the diagnosis is usually easy to
ascertain by standard radiographs. These demonstrate a
sclerosis that predominates in several sites, including the
spine (vertebral end-plate thickening, or Rugger-Jersey
spine), the pelvis (“bone-within-bone” structures), and
the skull base (fig. 1). However, the radiological pene-
trance is only 60%–90% (Bollerslev 1987; Be´nichou et
al. 2000a).
The genes involved in the dominant types of osteo-
petrosis are not yet known, but the gene underlying
ADO type I has been assigned to chromosome 11q12-
13 (Van Hul et al. 2000), precisely in the region where
a high-bone-mass syndrome has been localized (Johnson
et al. 1997). For ADO type II, we previously reported
a gene localization to chromosome 1p21 (Van Hul et al.
1997), after genotyping a Danish extended family by use
of markers surrounding the macrophage-specific colony-
stimulating factor (MCSF) gene (MIM 120420). How-
ever, the gene encoding MCSF was excluded by mapping
the gene outside the candidate region. It has since been
reported, however, that ADO type II was not linked to
1p21 in five other families with ADO type II (White et
al. 1999; Be´nichou et al. 2000a, and in press). In two
remaining families, linkage with this chromosomal re-
gion could not be excluded, but these families were too
small for conclusive results to be obtained (Be´nichou et
al. 2000a). These results already had suggested that
1p21 is only a minor locus in ADO type II.
To search for other loci involved in ADO type II, we
undertook a linkage study of five French families (A–E)
and one Danish family (F). These families have all been
described elsewhere: family A by Be´nichou et al. (in
press), families B–E by Be´nichou et al. (2000a), and fam-
ily F by Bollerslev (1987). The diagnosis of ADO type
II was ascertained by standard radiographs of the spine
and of the pelvis. In some individuals, bone-mineral den-
sitometry also was used to define the osteopetrotic phe-
notype (Be´nichou et al., in press). If there were indica-
Reports 649
tions of ADO type II in any of these three analyses, the
individual was considered to be affected.
In the six pedigrees, 114 family members, including 40
affected subjects, were willing to participate in the study,
after written, informed consent was obtained. Blood sam-
ples were collected from all of the participants, for DNA
extraction. The study was conducted in accordance with
the precepts of the Declaration of Helsinki, after agree-
ment by a local medical-ethics committee.
Genomic DNA was isolated from fresh leukocytes, by
standard techniques. The Co-operative Human Linkage
Centre Human Screening Set (Weber version 6) was used
in a genomewide linkage study of family A. This set
contains 391 fluorescently labeled, highly polymorphic
markers, with an average spacing of 10 cM, covering
the entire human genome. The markers were analyzed
by an automated sequencing apparatus (model 377; Ap-
plied Biosystems). Extra markers for regions of interest
were chosen from the Ge´ne´thon linkage map (Dib et al.
1996). These were analyzed by either radioactive-isotope
labeling or 5′–infra red dye (IRD) labeling. In the first
approach, radioactive end-labeling of one oligonucle-
otide was performed, with T7 polynucleotide kinase,
prior to PCR. Amplification products were separated,
according to size, on a 6% polyacrylamide gel and were
analyzed after autoradiography. In the second approach,
one of the primers is synthesized with an M13 forward
or reverse sequence on the 5′ end. An IRD-labeled (800
nm) M13 primer is included in the PCR reaction and is
incorporated from the second cycle, thus labeling the
PCR product. Gel electrophoresis and pattern visuali-
zation were performed by a LI-COR model 4200 DNA
analyzer Gene Readir (Westburg).
Two-point LOD scores were calculated by MLINK
version 5.1 (Lathrop and Lalouel 1984). The disease
frequency was set at 1/100,000. An autosomal dominant
mode of inheritance was assumed, with a disease pen-
etrance of 70%. Allele frequencies were set at ,where1/n
n is the number of observed alleles.
The pedigrees are shown in figure 2. All affected sub-
jects from families B–F displayed typical clinical and
radiological manifestations of ADO type II (Bollerslev
1987; Be´nichou et al. 2000a). In family A, manifesta-
tions were milder, as described elsewhere (Be´nichou et
al., in press). Clinical manifestations were less frequent
in this family than in the other families, although the
proband had already sustained three fractures at age !15
years (Be´nichou et al., in press). In four of nine affected
subjects in family A, the classic radiological sign de-
scribed as vertebral end-plate thickening was absent or
doubtful. In these subjects, the diagnosis was made on
the basis of either the presence of bone-within-bone sign,
especially in iliac wings or femoral heads, or a very high
spinal and femoral bone-mineral density dual X-ray ab-
sorptiometry (DXA; z score 14 SD).
In family A, linkage analysis throughout the whole
genome excluded 150% of the human genome.
D16S423 was the marker most suggestive for linkage,
with a maximum LOD score of 3.73 at a recombination
fraction (v) of 0 (table 1). To confirm these data, extra
markers from this region were analyzed. The maximum
LOD score of 4.05 at was obtained with markersvp 0
D16S3082 and D16S3027 (table 1), confirming the link-
age between ADO type II and this chromosomal region,
in family A. Analysis of four other French families (fam-
ilies B–E) illustrated cosegregation between a chromo-
some 16p13.3 haplotype and ADO type II in each of
these families (fig. 2). The LOD scores obtained in family
B are conclusive—that is, 13—for two markers (table
1). The restricted size of families C–E, however, makes
impossible conclusive assignment in these families. Fi-
nally, we analyzed the Danish family (family F), which
previously had been shown to have linkage to chro-
mosome 1p21. Unexpectedly, a chromosome 16p13.3
haplotype cosegregating with ADO type II was found
also in this family, generating significant positive LOD
scores for several markers (table 1). In family F, the max-
imum LOD score of 4.21 was obtained with marker
D16S3027, at . These results are comparable withvp 0
those obtained with chromosome 1 markers, with a
maximum two-point LOD score of 3.65, for marker
D1S495, increasing to 4.09 in multipoint analysis (Van
Hul et al. 1997). There are two ways in which these
results can be explained. First, cosegregation between a
disease and, simultaneously, two chromosomal regions
can occur under a digenic model. In our case, this ex-
planation is very unlikely, since—aside from the fact that
the majority of the other families with ADO type II do
not have linkage to chromosome 1p21—the reoccur-
rence rate in family F is ∼50%, whereas under a digenic
model only 25% is expected. Therefore, the second and
more likely explanation is that one of the two sugges-
tions for linkage is due only to incidental cosegregation.
Several at-risk individuals (FII-6, FIII-8, FIII-29, and
FIII-36) without any clinical or radiological signs of the
disease, inherited the affected haplotype for only one of
the two chromosomal regions. However, owing to the
reduced penetrance, this does not provide a clear indi-
cation as to which of the two assignments might be
spurious. Given that, thus far, conclusive evidence for
genetic linkage to chromosome 1p21 could be obtained
only in family F—whereas, in this study, cosegregation
between ADO type II and chromosome 16p13.3 was
observed in all families—we clearly favor the hypothesis
that 16p13.3 is the gene locus in family F also.
The delineation of the candidate region for the ADO
type II gene is based on recombination events that occur
in the families. Because of the reduced penetrance of
ADO type II, only those recombinants that occurred in
affected individuals can be taken into account. Since, at
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Figure 2 A–F, Pedigrees of families A–F, respectively. Squares represent males, and circles represent females. Blackened symbols indicate
affected individuals, and unblackened symbols indicate individuals without clinical or radiological signs. The haplotypes from the chromosome
16p13.3 markers are shown below the symbols. The order of the seven markers analyzed is, from telomere (top) to centromere (bottom), D16S521,
D16S3024, D16S3082, D16S3027, D16S423, D16S3030, and D16S3128. Blackened bars indicate the haplotype that cosegregates with the disease.
this point, genetic heterogeneity for ADO type II cannot
be excluded, the most conservative approach is to in-
clude only those families who have been proved to be
linked (i.e., families A and B). On the telomeric side, no
recombinant is present, whereas, on the proximal side,
marker D16S3030 is recombining in individuals AIII-15
and AIV-4, an obligate carrier and his affected son, re-
spectively (fig. 3). This delineates a candidate region of
10.6 cM, starting from 16pter. As discussed above, we
favor the possibility that the linkage results obtained in
family F, with markers from chromosome 16p13.3, re-
flect the real gene assignment. On the basis of this as-
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sumption, recombinations in individual FIII-26 enable
us to narrow the candidate region to 8.4 cM between
markers D16S423 and D16S521 (fig. 3). A recombi-
nation event in the candidate region seen in family B
(individual BIV-9), cannot, at this point, contribute to
the delineation of the candidate region, since this indi-
vidual is unaffected; however, this might be due to non-
penetrance. To further narrow the candidate region, we
looked for (partial) haplotypes shared among the af-
fected individuals from different families, assuming that
some of them might be related, although we were not
able to find any evidence of this (data not shown).
Since the candidate region delineated for ADO type II
still is of respectable size, it includes a large number of
genes. Of the genes currently assigned to this chromo-
somal region, two in particular are definitely to be con-
sidered as candidate genes for ADO type II. The first is
the CLCN7 gene, which encodes a chloride-channel pro-
tein that is highly expressed in osteoclasts and in which
mutations recently have been found in a child with ma-
lignant recessive osteopetrosis (Kornak et al. 2001). The
function of this protein is to provide chloride conduc-
tance, which is obligatory for efficient proton pumping
to generate the acidic extracellular environment necessary
Table 1
Pairwise LOD Scores between ADO Type II and Seven Chromosome 16p13.3 Markers
MARKER AND FAMILY
LOD SCORE
At v p
For Affecteds
Only (vp0)0 .01 .05 .10 .20 .30 .40
D16S521:
A 3.53 3.48 3.29 3.01 2.36 1.57 .65
B .35 .35 .31 .27 .19 .12 .06
C .94 .92 .82 .70 .46 .23 .06
D .29 .29 .28 .26 .19 .10 .03
E .00 .00 .00 .00 .00 .00 .00
F 2.04 .44 1.09 1.29 1.25 .93 .44
Total 3.07 5.48 5.79 5.53 4.45 2.95 1.24
D16S3024:
A 2.34 2.31 2.20 2.03 1.59 1.02 .36 1.78
B 3.19 3.13 2.87 2.54 1.86 1.15 .46 1.54
C .98 .96 .86 .73 .48 .25 .07 .48
D .29 .29 .28 .26 .19 .10 .03 .48
E .68 .66 .60 .52 .36 .19 .06 .30
F 3.17 3.13 2.99 2.77 2.23 1.53 .71 3.05
Total 10.65 10.48 9.80 8.85 6.71 4.24 1.69 7.63
D16S3082:
A 4.05 3.99 3.75 3.41 2.66 1.76 .75 2.28
B 2.76 2.71 2.50 2.21 1.61 .96 .32 1.23
C 1.00 .98 .88 .75 .50 .26 .08 .48
D .38 .37 .35 .31 .21 .11 .03 .48
E .68 .66 .60 .52 .36 .19 .06 .30
F 1.29 1.28 1.26 1.20 1.01 .73 .40 1.93
Total 10.16 9.99 9.34 8.40 6.35 4.01 1.64 6.70
D16S3027:
A 4.05 3.99 3.74 3.41 2.65 1.75 .74 2.69
B 3.06 3.01 2.77 2.45 1.78 1.07 .37 1.53
C 1.00 .98 .88 .75 .50 .26 .08 .48
D .38 .37 .35 .31 .21 .11 .03 .48
E .00 .00 .00 .00 .00 .00 .00 .00
F 4.21 4.16 3.93 3.62 2.87 1.99 .95 3.56
Total 12.70 12.51 11.67 10.54 8.01 5.18 2.17 8.74
D16S423:
A 3.73 3.67 3.41 3.07 2.30 1.44 .54
B 2.41 2.37 2.21 1.98 1.49 .95 .40
C .14 .13 .11 .09 .05 .03 .01
D 3.19 1.15 .50 .25 .06 .00 .01
E .15 .15 .14 .13 .09 .04 .01
F 2.73 1.84 2.37 2.41 2.09 1.51 .74
Total .51 7.01 7.74 7.43 5.96 3.97 1.71
D16S3030:
A 1.11 .85 1.40 1.48 1.28 .86 .33
B 2.67 2.62 2.43 2.17 1.60 .98 .38
C 3.90 1.18 .53 .29 .11 .04 .01
D .41 .40 .36 .31 .21 .11 .03
E .15 .15 .14 .13 .09 .04 .01
F 2.63 .09 1.12 1.45 1.45 1.08 .55
Total 4.41 2.75 4.92 5.25 4.52 3.03 1.29
D16S3128:
A 1.85 .13 .71 .86 .81 .60 .34
B 2.09 2.06 1.90 1.69 1.21 .69 .20
C 3.90 1.18 .53 .29 .11 .04 .01
D 3.35 1.13 .63 .34 .10 .01 .01
E .15 .15 .14 .13 .09 .04 .01
F 2.93 .34 .91 1.31 1.38 1.0 .57
Total 9.79 .31 2.50 3.36 3.28 2.35 1.12
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Figure 3 Ideogram of chromosome 16 and genetic map of markers used to delineate candidate region. The candidate region is shown as a
blackened bar on the first vertical line, and the intermarker distances (in cM) are given. On the other vertical lines, blackened bars indicate those
regions that cosegregate, and unblackened bars indicate regions that recombine and that therefore cannot contain the disease gene. The lines between
rectangles indicate uninformative regions.
for the degradation of bone tissue. This proton pumping
is performed by a vacuolar H-ATPase protein complex
comprising 13 subunits. The gene encoding thea3 subunit
of this protein complex has been shown to be mutated
in a subset of patients with recessive osteopetrosis (Frattini
et al. 2000; Kornak et al. 2000). Since the gene encoding
another subunit (ATP6L [MIM 108745]) of the vacuolar
H-ATPase protein complex is located in the region,
on chromosome 16p13.3, delineated for ADO type II
(Gillespie et al. 1991), this gene needs to be considered
as a candidate disease gene also.
In conclusion, we have provided evidence that a major
gene for ADO type II is on chromosome 16p13.3.More-
over, analysis of what is thus far the only family with
ADO type II assigned to chromosome 1p21 indicates
that this previous assignment might be due only to in-
cidental cosegregation and that ADO type II might still
be genetically homogeneous because of a single, still-
unidentified gene on chromosome 16p13.3. Identifica-
tion of this gene will definitely provide further insight
into the processes of bone metabolism—more specifi-
cally, that of bone resorption.
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